Company intelligence / Profile preview
Adiso Therapeutics
Concord, Massachusetts, United Statesadisotx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Adiso has multiple clinical programs including ADS051 in Phase 2 for ulcerative colitis, ADS032 in IND enabling stage for respiratory and dermal conditions, and ADS024 in preclinical development for neuroinflammation. The company has completed enrollment in the third cohort of its Phase 1b study of ADS051 for moderate-to-severe ulcerative colitis.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyNeurologyInfectious Diseases
- Modalities
- Small moleculesSingle strain live biotherapeutic products (SS-LBP)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Adiso Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adiso Therapeutics.